Our COO Jessica Rousset did a quick interview with Proactive Investors last week.

She discussed the CURE Pharmaceutical licensing deal with Canopy Growth Corp where Canopy will have an exclusive license to our patented, multi-layer oral thin film technology for use with cannabis extracts and biosynthetic cannabinoids.

The license agreement allows CURE to accelerate and expand the impact of our technology by joining forces with Canopy, which has broad market access and resources to bring a product to market.